Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori

References

• Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321–333. doi:10.1172/JCI20925
   PubMed Web of Science ®Google Scholar
• Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori: the past, present, and future in management. Mayo Clin Proc. 2017;92:599–604. doi:10.1016/j.mayocp.2016.11.017
   PubMed Web of Science ®Google Scholar
• Romano M, Ricci V, Zarrilli R. Mechanisms of disease: helicobacter pylori-related gastric carcinogenesis—implications for chemoprevention. Nat Rev Gastroenterol Hepatol. 2006;3:622.
   Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278. doi:10.1111/hel.2007.12.issue-4
   PubMed Web of Science ®Google Scholar
• Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186. doi:10.1056/NEJMra020542
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Bazzoli F, Delchier J. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, Phase 3 trial (vol 377, pg 905, 2011). Lancet. 2011;378:1778.
   Web of Science ®Google Scholar
• Zhao F, Wang J, Yang Y, et al. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor‐based triple therapy for Helicobacter pylori eradication: a meta‐analysis. Helicobacter. 2008;13:532–541. doi:10.1111/hel.2008.13.issue-6
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42. doi:10.1136/gutjnl-2012-302254
   PubMed Web of Science ®Google Scholar
• Cosme A, Montes M, Ibarra B, et al. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World j Gastroenterol. 2017;23:3367–3373. doi:10.3748/wjg.v23.i18.3367
   PubMed Web of Science ®Google Scholar
• Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2008;5:321.
   Web of Science ®Google Scholar
• Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007;56:475–479. doi:10.1136/gut.2006.102269
   PubMed Web of Science ®Google Scholar
• Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: a recent literature review. World J Methodol. 2015;5:164–174. doi:10.5662/wjm.v5.i3.164
   PubMedGoogle Scholar
• Fischbach L, Evans E. Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357. doi:10.1111/apt.2007.26.issue-3
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–781. doi:10.1136/gut.2006.101634
   PubMed Web of Science ®Google Scholar
• Park JY, Dunbar KB, Mitui M, et al. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig Dis Sci. 2016;61:2373–2380. doi:10.1007/s10620-016-4091-8
   Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’morain C, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.
   PubMed Web of Science ®Google Scholar
• Nista EC, Candelli M, Zocco MA, et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol. 2006;101:1985. doi:10.1111/j.1572-0241.2006.00716.x
   PubMed Web of Science ®Google Scholar
• Gisbert J, De La Morena F. Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35–44. doi:10.1111/apt.2006.23.issue-1
   PubMed Web of Science ®Google Scholar
• Kahramanoglu Aksoy E, Pirincci Sapmaz F, Goktas Z, Uzman M, Nazligul Y. Comparison of Helicobacter pylori eradication rates of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen. Med Princ Pract. 2017;26:523–529. doi:10.1159/000484930
   Web of Science ®Google Scholar
• Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: a 1-week, open-label, randomized trial. Medicine. 2017;96:e5859. doi:10.1097/MD.0000000000005859
   Web of Science ®Google Scholar
• Yee Y, Cheung T, Chu KM, et al. Clinical trial: levofloxacin‐based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2007;26:1063–1067. doi:10.1111/j.1365-2036.2007.03452.x
   PubMed Web of Science ®Google Scholar
• Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59:1465–1470. doi:10.1136/gut.2010.215350
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World j Gastroenterol. 2008;14:6065–6071. doi:10.3748/wjg.14.6065
   PubMed Web of Science ®Google Scholar
• Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi:10.1136/bmj.g3174
   PubMed Web of Science ®Google Scholar
• Sverden E, Brusselaers N, Wahlin K, Lagergren J. Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study. Gastrointest Endosc. 2018;88:242–250.e1. doi:10.1016/j.gie.2017.11.035
   PubMed Web of Science ®Google Scholar
• Pajares JM, Gisbert JP. Helicobacter pylori: its discovery and relevance for medicine. Rev Esp Enferm Dig. 2006;98:770–785. doi:10.4321/s1130-01082006001000007
   Web of Science ®Google Scholar
• NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65–69. doi:10.1001/jama.272.1.65
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’morain C, et al. Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. Eur J Gastroenterol Hepatol. 1997;9:1–2. doi:10.1097/00042737-199701000-00002
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X, O’Connor A, Megraud F, O’Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44:313–325. doi:10.1097/MCG.0b013e3181c8a1a3
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi:10.1136/gut.2009.192757
   PubMed Web of Science ®Google Scholar
• Seven G, Cinar K, Yakut M, Idilman R, Ozden A. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin. Turkish J Gastroenterol. 2011;22:582–586. doi:10.4318/tjg.2011
   Web of Science ®Google Scholar
• Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Fejza H. The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication. Med Archiv. 2013;67:348–350. doi:10.5455/medarh.2013.67.348-350
   Google Scholar
• Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:1339–1343. doi:10.1046/j.1365-2036.2000.00846.x
   PubMed Web of Science ®Google Scholar
• Antos D, Schneider‐Brachert W, Bästlein E, et al. 7‐day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high‐dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter. 2006;11:39–45. doi:10.1111/j.0083-8703.2006.00375.x
   Web of Science ®Google Scholar
• Gisbert J, Fernandez‐Bermejo M, Molina‐Infante J, et al. First‐line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2007;26:495–500. doi:10.1111/j.1365-2036.2007.03384.x
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo MF, Infante JM, et al. Levofloxacin, amoxicillin, and omeprazole as first-line triple therapy for Helicobacter pylori eradication. J Clin Gastroenterol. 2009;43:384–385. doi:10.1097/MCG.0b013e31816d921c
   Web of Science ®Google Scholar
• Schrauwen R, Janssen M, De Boer W. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med. 2009;67:96–101.
   Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239. doi:10.1038/ajg.2016.563
   PubMed Web of Science ®Google Scholar
• Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378:507–514. doi:10.1016/S0140-6736(11)60825-8
   PubMed Web of Science ®Google Scholar
• Fraser A, Delaney BC, Ford AC, Qume M, Moayyedi P. The Short-Form Leeds Dyspepsia Questionnaire validation study. Aliment Pharmacol Ther. 2007;25:477–486. doi:10.1111/j.1365-2036.2006.03233.x
   Web of Science ®Google Scholar
• Gisbert JP, Perez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013;47:130–135. doi:10.1097/MCG.0b013e318254ebdd
   Web of Science ®Google Scholar
• Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14‐day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter. 2013;18:373–377. doi:10.1111/hel.2013.18.issue-5
   PubMed Web of Science ®Google Scholar
• Abadi ATB, Ghasemzadeh A, Taghvaei T, Mobarez AM. Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med. 2012;7:447–452. doi:10.1007/s11739-011-0563-1
   PubMed Web of Science ®Google Scholar
• Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol. 2011;26:1457–1461. doi:10.1111/j.1440-1746.2011.06815.x
   PubMed Web of Science ®Google Scholar
• Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in Helicobacter pylori isolates in Bogotá-Colombia (2009-2014). PLoS One. 2016;11:e0160007. doi:10.1371/journal.pone.0160007
   PubMed Web of Science ®Google Scholar
• Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Digest Liver Dis. 2007;39:1001–1005. doi:10.1016/j.dld.2007.06.016
   Web of Science ®Google Scholar
• O’Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci. 2013;182:693–695. doi:10.1007/s11845-013-0957-3
   Web of Science ®Google Scholar
• Zullo A, Perna F, Hassan C, et al. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther. 2007;25:1429–1434. doi:10.1111/(ISSN)1365-2036
   PubMed Web of Science ®Google Scholar
• Georgopoulos SD, Ladas SD, Karatapanis S, et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. Dig Dis Sci. 2000;45:63–67. doi:10.1023/A:1005405209503
   PubMed Web of Science ®Google Scholar
• Carabotti M, D’Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery. World j Gastroenterol. 2014;20:647–653. doi:10.3748/wjg.v20.i3.647
   PubMed Web of Science ®Google Scholar
• Osawa H. Ghrelin and Helicobacter pylori infection. World j Gastroenterol. 2008;14:6327–6333. doi:10.3748/wjg.14.6327
   Web of Science ®Google Scholar
• Arslan E, Atilgan H, Yavasoglu I. The prevalence of Helicobacter pylori in obese subjects. Eur J Intern Med. 2009;20:695–697. doi:10.1016/j.ejim.2009.07.013
   PubMed Web of Science ®Google Scholar